A detailed history of Thrivent Financial For Lutherans transactions in Neurocrine Biosciences Inc stock. As of the latest transaction made, Thrivent Financial For Lutherans holds 25,802 shares of NBIX stock, worth $3.24 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares
25,802
Previous 46,577 44.6%
Holding current value
$3.24 Million
Previous $6.41 Million 53.63%
% of portfolio
0.01%
Previous 0.01%

Shares

29 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 07, 2024

SELL
$114.58 - $153.15 $2.38 Million - $3.18 Million
-20,775 Reduced 44.6%
25,802 $2.97 Million
Q2 2024

Aug 13, 2024

BUY
$130.86 - $143.19 $2.83 Million - $3.1 Million
21,641 Added 86.79%
46,577 $6.41 Million
Q1 2024

May 14, 2024

BUY
$130.4 - $143.74 $50,986 - $56,202
391 Added 1.59%
24,936 $3.44 Million
Q4 2023

Feb 14, 2024

BUY
$106.07 - $132.76 $9,970 - $12,479
94 Added 0.38%
24,545 $3.23 Million
Q3 2023

Nov 14, 2023

SELL
$94.02 - $117.1 $69,010 - $85,951
-734 Reduced 2.91%
24,451 $2.75 Million
Q2 2023

Aug 14, 2023

SELL
$89.53 - $104.87 $27,306 - $31,985
-305 Reduced 1.2%
25,185 $2.38 Million
Q1 2023

May 17, 2023

SELL
$94.11 - $123.02 $450,034 - $588,281
-4,782 Reduced 15.8%
25,490 $2.58 Million
Q4 2022

Feb 08, 2023

BUY
$106.72 - $127.06 $529,224 - $630,090
4,959 Added 19.59%
30,272 $3.62 Million
Q3 2022

Nov 14, 2022

BUY
$92.03 - $107.81 $21,903 - $25,658
238 Added 0.95%
25,313 $2.69 Million
Q2 2022

Aug 16, 2022

BUY
$75.79 - $100.07 $21,600 - $28,519
285 Added 1.15%
25,075 $2.44 Million
Q1 2022

May 13, 2022

SELL
$72.45 - $94.81 $16,228 - $21,237
-224 Reduced 0.9%
24,790 $2.32 Million
Q4 2021

Feb 16, 2022

BUY
$79.65 - $106.22 $21,903 - $29,210
275 Added 1.11%
25,014 $2.13 Million
Q3 2021

Nov 15, 2021

SELL
$86.18 - $99.03 $31,024 - $35,650
-360 Reduced 1.43%
24,739 $2.37 Million
Q2 2021

Aug 19, 2021

BUY
$89.43 - $102.27 $11,089 - $12,681
124 Added 0.5%
25,099 $2.44 Million
Q1 2021

May 17, 2021

BUY
$87.57 - $119.4 $2.19 Million - $2.98 Million
24,975 New
24,975 $2.43 Million
Q4 2020

Feb 16, 2021

SELL
$86.91 - $108.33 $3.1 Million - $3.86 Million
-35,625 Closed
0 $0
Q3 2020

Nov 10, 2020

SELL
$96.16 - $135.15 $18.5 Million - $26 Million
-192,400 Reduced 84.38%
35,625 $3.43 Million
Q2 2020

Aug 12, 2020

BUY
$85.09 - $130.36 $91,471 - $140,137
1,075 Added 0.47%
228,025 $27.8 Million
Q1 2020

May 15, 2020

SELL
$75.11 - $113.76 $3,680 - $5,574
-49 Reduced 0.02%
226,950 $19.6 Million
Q4 2019

Feb 13, 2020

BUY
$86.8 - $118.57 $1.78 Million - $2.43 Million
20,464 Added 9.91%
226,999 $24.4 Million
Q3 2019

Nov 14, 2019

BUY
$83.82 - $101.5 $517,672 - $626,864
6,176 Added 3.08%
206,535 $18.6 Million
Q2 2019

Aug 13, 2019

BUY
$72.24 - $91.27 $1.07 Million - $1.35 Million
14,752 Added 7.95%
200,359 $16.9 Million
Q1 2019

May 14, 2019

SELL
$69.31 - $91.53 $35.1 Million - $46.3 Million
-506,244 Reduced 73.17%
185,607 $16.4 Million
Q4 2018

Feb 15, 2019

BUY
$68.32 - $124.36 $23 Million - $41.8 Million
336,101 Added 94.48%
691,851 $49.4 Million
Q3 2018

Nov 15, 2018

BUY
$98.88 - $125.85 $10 Million - $12.8 Million
101,517 Added 39.93%
355,750 $43.7 Million
Q2 2018

Aug 14, 2018

BUY
$75.3 - $105.99 $213,400 - $300,375
2,834 Added 1.13%
254,233 $25 Million
Q1 2018

May 08, 2018

SELL
$75.88 - $92.43 $27,620 - $33,644
-364 Reduced 0.14%
251,399 $20.8 Million
Q4 2017

Feb 14, 2018

SELL
$58.53 - $77.59 $48,579 - $64,399
-830 Reduced 0.33%
251,763 $19.5 Million
Q3 2017

Nov 14, 2017

BUY
$47.97 - $61.28 $12.1 Million - $15.5 Million
252,593
252,593 $15.5 Million

Others Institutions Holding NBIX

About NEUROCRINE BIOSCIENCES INC


  • Ticker NBIX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 95,639,296
  • Market Cap $12B
  • Description
  • Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, ...
More about NBIX
Track This Portfolio

Track Thrivent Financial For Lutherans Portfolio

Follow Thrivent Financial For Lutherans and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Thrivent Financial For Lutherans, based on Form 13F filings with the SEC.

News

Stay updated on Thrivent Financial For Lutherans with notifications on news.